Loading cancer entity…
Loading cancer entity…
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06843967 | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 |
| clinicaltrials |
| NCT06083883 | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | recruiting | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06414434 | BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | active not recruiting | Phase 1 | 24 | Michael Wagner, MDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | terminated | Phase 1 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | unknown | Phase 1 | 50 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03450122 | Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients(TRASTS) | recruiting | Phase 1 / Phase 2 | 199 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | May 31, 2023 | clinicaltrials |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2016 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials